Abbott Laboratories Aktie
WKN: 850103 / ISIN: US0028241000
20.07.2022 14:06:56
|
Abbott Q2 Profit Tops Estimates; Raises 2022 Earnings Guidance
(RTTNews) - Abbott (ABT) said it recorded another quarter of strong growth with an increase in adjusted earnings per share of 22.2 percent year-over-year. Sales were up 14.3 percent on an organic basis, which excludes the impact of foreign exchange. Looking forward, the company increased its full-year 2022 EPS guidance. The company noted that its 2022 guidance includes projected COVID-19 testing-related sales of $6.1 billion, which includes sales of $5.6 billion through June 2022 and projected sales of $500 million over the next few months.
Excluding items, second-quarter adjusted EPS was $1.43 compared to $1.17, prior year. On average, 18 analysts polled by Thomson Reuters expected the company to report profit per share of $1.12, for the quarter. Analysts' estimates typically exclude special items. Net earnings excluding specified items was $2.54 billion, up 20.2% from previous year.
GAAP net earnings were $2.02 billion, an increase of 69.7% from prior year. EPS was $1.14 compared to $0.66, last year.
Second-quarter worldwide sales were $11.3 billion, up 10.1 percent on a reported basis. Global COVID-19 testing-related sales were $2.3 billion in the second quarter. Worldwide sales, excluding COVID-19 testing-related sales, decreased 0.3 percent on a reported basis and increased 4.1 percent on an organic basis. Analysts on average had estimated $10.29 billion in revenue.
The company noted that its worldwide sales were negatively impacted by a voluntary recall and manufacturing shutdown initiated in February of certain infant formula products manufactured at one of Abbott's U.S. plants. Excluding COVID-19 testing-related sales and the U.S. sales associated with the recalled products in the current and prior years, total worldwide sales increased 1.6 percent on a reported basis and 6.2 percent on an organic basis in the second quarter.
Abbott increased its full-year 2022 GAAP earnings per share guidance to at least $3.50. Abbott forecasts specified items for the full-year 2022 of $1.40 per share primarily related to intangible amortization, costs related to a voluntary recall, expenses associated with acquisitions, restructurings and cost reduction initiatives and other net expenses. Excluding specified items, Abbott raised its projected adjusted earnings per share to at least $4.90 for 2022. Analysts expect the company to report profit per share of $4.88.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Abbott Laboratoriesmehr Nachrichten
23.04.25 |
NASDAQ Composite aktuell: NASDAQ Composite mittags in Grün (finanzen.at) | |
23.04.25 |
Optimismus in New York: NASDAQ Composite hebt zum Start ab (finanzen.at) | |
17.04.25 |
NASDAQ Composite Index-Titel Abbott Laboratories-Aktie: So viel Gewinn hätte ein Investment in Abbott Laboratories von vor 5 Jahren eingebracht (finanzen.at) | |
16.04.25 |
Verluste in New York: S&P 500 zeigt sich schlussendlich leichter (finanzen.at) | |
16.04.25 |
NASDAQ-Handel NASDAQ Composite tiefrot (finanzen.at) | |
16.04.25 |
Schwacher Handel in New York: S&P 500 notiert am Mittwochnachmittag im Minus (finanzen.at) | |
16.04.25 |
S&P 500 aktuell: S&P 500 am Mittag in der Verlustzone (finanzen.at) | |
16.04.25 |
Börse New York: NASDAQ Composite präsentiert sich leichter (finanzen.at) |
Analysen zu Abbott Laboratoriesmehr Analysen
Aktien in diesem Artikel
Abbott Laboratories | 114,14 | -0,73% |
|